Natalie McClure is VP at Adamas Pharmaceuticals Inc (ADMS). They have made 1 open-market trade across 1 company since 2014, most recently 2016-04-18.
CIK 0001604572
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADMS | 21,006 | $173K |
Shares reported on the most recent Form 4, priced at the 2016-04-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMS | SELL | 2016-04-18 | 2016-04-20 | $18.50 | $666K | -1.4% | -8.2% | -14.0% |
| ADMS | SELL · 10b5-1 | 2015-06-05 | 2015-06-09 | $18.95 | $38K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-05-05 | 2015-05-07 | $17.62 | $35K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-04-06 | 2015-04-07 | $17.44 | $35K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-03-05 | 2015-03-09 | $17.15 | $34K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-02-05 | 2015-02-06 | $16.87 | $34K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2015-01-05 | 2015-01-07 | $17.59 | $35K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2014-12-05 | 2014-12-09 | $14.01 | $28K | -13.8% | +0.8% | +0.8% |
| ADMS | SELL · 10b5-1 | 2014-12-01 | 2014-12-03 | $14.50 | $290K | -13.8% | +0.8% | +0.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.